ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1433	National Cancer Institute	Html	en	Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version	Expert-reviewed information summary about the genetics of breast and gynecologic cancers, including information about specific genes and family cancer syndromes. The summary also contains information about interventions that may influence the risk of developing breast and gynecologic cancers in individuals who may be genetically susceptible to these diseases. Psychosocial issues associated with genetic testing are also discussed.	Pregnancy-associated breast cancer 0.506333 total breast cancer 0.488298 primary breast cancer 0.498056 BRCA1 pathogenic variants 0.493823 Prospective breast cancer 0.487994 Br J Cancer 0.484038 Int J Cancer 0.495039 individual breast cancer 0.489704 cancer risk reduction 0.475227 triple-negative breast cancer 0.516988 breast cancer decline 0.488175 ovarian cancer 0.654478 breast cancer patients 0.493005 postmenopausal breast cancer 0.500017 breast cancer risk. 0.510237 cancer risk assessment 0.501046 Natl Cancer Inst 0.80311 Ovarian Cancer Group 0.476381 BRCA1-associated breast cancer 0.507407 invasive breast cancer 0.506617 endometrial cancer 0.505116 hormone replacement therapy 0.500252 breast cancer prediction 0.489793 et al. 0.567541 BRCA2 mutation carriers 0.531322	women 0.515983 contralateral breast cancer 0.498075 early breast cancer 0.50631 early-onset breast cancer 0.489583 nonpolyposis colorectal cancer 0.483231 breast cancer family 0.518542 breast cancer diagnosis 0.495632 BOADICEA breast cancer 0.48834 PUBMED Abstract 0.498618 pathogenic variants 0.552407 Cancer Res Treat 0.576792 Breast Cancer Treatment 0.508531 epithelial ovarian cancer 0.48165 ovarian cancer risk 0.536184 breast cancer risk 0.765155 Abstract 0.613814 breast cancer survival 0.499805 breast cancer 0.946746 breast cancer mortality 0.506691 Breast cancer cluster 0.487434 family history 0.570688 breast cancer incidence 0.492239 familial breast cancer 0.49066 Breast Cancer Res 0.640001	CLICK HERE
1435	National Cancer Institute	Html	en	Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood extracranial germ cell tumors.	testicular germ cell 0.206027 treatment 0.243869 germ cell tumors 0.902772 stage 0.204984 extracranial germ cell 0.708761	ovarian germ cell 0.212137 childhood extracranial germ 0.398861 cancer 0.399843 clinical trials 0.265215	CLICK HERE
1535	National Cancer Institute	Html	en	Hydrazine Sulfate (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of hydrazine sulfate as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	single agent 0.446847 measurable tumor regression 0.444265 hydrazine sulfate group 0.561221 stable disease 0.438607 hydrazine sulfate therapy. 0.512358 advanced nonsmall cell 0.439337 body weight 0.435692 prostate cancer tumors 0.435725 best tumor responses 0.433645 anticancer treatment 0.440366 white blood cells 0.437041 bladder cancer tumors 0.452946 clinical trials 0.508473 cancer information summary 0.434117 clinical drug research 0.432809 placebo group 0.446705 patients 0.531553 FBCa bladder cancer 0.447874 cancer patients 0.442585 hydrazine sulfate therapy 0.539457 complete responses 0.433235 multiple-drug chemotherapy regimen 0.457646 breakdown products 0.436734 human tumor cells 0.434705 radiation therapy 0.432799	anticancer activity 0.483124 hydrazine sulfate research 0.543056 treatment 0.474001 United States 0.450385 hydrazine sulfate administration 0.532876 National Toxicology Program 0.441282 nonsmall cell lung 0.4545 clinical series 0.445474 hydrazine compounds 0.479897 hydrazine analogs 0.451642 National Cancer Institute 0.447177 tumor growth 0.446716 partial responses 0.440765 Cancer Treatment Group 0.438635 hydrazine sulfate blocks 0.527938 hydrazine antidepressants 0.434523 enhanced antitumor activity 0.43882 advanced cancer 0.436974 animal studies 0.436395 hydrazine sulfate 0.995392 Hydrazine administration 0.434303 cell lung cancer 0.443379 objective tumor response 0.459617 clinical studies 0.444539	CLICK HERE
1568	National Cancer Institute	Html	en	Gastrointestinal Carcinoid Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of gastrointestinal carcinoid tumors.	carcinoid tumor cells 0.278965 metastatic GI carcinoid 0.238039 treatment 0.556764 cancer treatment 0.277356 malignant tumor cells 0.240006 general information 0.281992 GI carcinoid tumors 0.692008 Hormone therapy 0.212489 Lung Cancer Treatment 0.223918 NCI-supported cancer 0.254433 cancer cells 0.281516 stomach 0.228344 hepatic artery 0.21097 body 0.300003 type 0.211866 PDQ cancer information 0.277061 clinical trial search 0.358585 carcinoid tumor spreads 0.266506 treatment clinical trials 0.240478 recurrent GI carcinoid 0.223511 National Cancer Institute 0.243506 clinical trials 0.834392 tumor cells 0.308788	Carcinoid Tumors Treatment 0.268829 cancer information summary 0.243151 clinical trial 0.501578 new treatment 0.293328 Rectal Cancer Treatment 0.224504 liver 0.203338 gastrointestinal carcinoid tumor 0.314953 patients 0.237822 carcinoid heart syndrome 0.215848 carcinoid tumor tissue 0.264996 carcinoid syndrome 0.334872 metastatic tumor 0.206035 blood 0.210445 cancer clinical trials 0.359168 lymph nodes 0.28707 carcinoid tumors 0.943574 radiation therapy 0.236209 internal radiation therapy 0.21238 cancer 0.673084 information 0.294151 small intestine 0.264836 gastrointestinal carcinoid tumors 0.573326 Intestine Cancer Treatment 0.236505	CLICK HERE
1651	National Cancer Institute	Html	en	Milk Thistle (PDQ®)–Patient Version	Expert-reviewed information summary about the use of milk thistle as a treatment for people with cancer.	cancer treatment 0.701214 advanced liver cancer 0.66555 PDQ cancer information 0.729457 Cancer Complementary 0.666923 clinical trials 0.798052 U.S. Food 0.649163 cancer information summary 0.699946 alternative cancer therapies 0.663524 clinical trial 0.731299 CAM cancer research 0.657056 patients 0.673877 cancer patients 0.654835 randomized clinical trial 0.683387 Marian thistle 0.690666 NCI PDQ cancer 0.677418 cancer information database 0.662437 radiation therapy 0.660512 Therapies Editorial Board 0.664492 cancer information 0.734643 treatment 0.70795 cancer prevention 0.650452 Complementary Therapies Editorial 0.677699 United States 0.665688 Drug Administration 0.682045	Cancer Information Specialist 0.658528 cancer cells 0.669779 milk thistle supplements 0.741182 cancer cell lines 0.655527 anticancer medications 0.651405 Cancer Information Service 0.697895 CAM therapies 0.649867 treatment clinical trials 0.654645 National Cancer Institute 0.770559 alternative medicine 0.692591 conventional treatment 0.650077 St. Mary thistle 0.707197 Federal Trade Commission 0.651646 silymarin 0.670265 Cancer Care page 0.650369 breast cancer 0.668147 PDQ summary 0.650118 cancer clinical trials 0.667946 alternative therapies 0.674881 acute lymphoblastic leukemia 0.665296 neck cancer 0.65549 cancer information summaries 0.662842 colorectal cancer cells 0.652543 cancer 0.828322	CLICK HERE
1678	National Cancer Institute	Html	en	Communication in Cancer Care (PDQ®)–Health Professional Version	Effective cancer communication between the health care team, cancer patients, and their family is important. Learn about communication skills that support a patient-centered practice and how to talk with adults and children about their diagnosis, prognosis, and transition to end-of-life care in this expert-reviewed summary.	female breast cancer 0.57505 eligible patients 0.564938 bad news 0.743613 medical decision making 0.58503 physicians 0.592367 direct patient care 0.564892 diverse cancer patients 0.603459 clinical trials 0.61877 communication 0.630971 early-stage breast cancer 0.592631 patients cultural beliefs 0.582353 breast cancer experience 0.564126 breast cancer treatment 0.579002 breast cancer patients 0.646574 patients 0.906881 cancer patients 0.64886 white patients 0.564203 cancer diagnosis 0.569139 health care costs 0.565569 cancer patients report 0.596785 decision making 0.744128 breast cancer therapy 0.566081 treatment decision making 0.568266 older breast cancer 0.566807 care 0.590659	treatment 0.626966 American oncology patients 0.58299 study 0.656108 patient communication preferences 0.600601 cancer disclosure issues 0.56732 African American patients 0.584216 different information styles 0.572854 Asian American women 0.565505 patient decision making 0.57769 black patients 0.564183 younger patients 0.563325 high information needs 0.57343 health care 0.579997 patient information style 0.59028 older patients 0.579527 initial cancer diagnosis 0.562722 Cancer care 0.562573 breast cancer 0.780881 specific treatment information 0.578443 patient satisfaction 0.579033 information patients 0.586119 treatment options 0.585641 rural American patients 0.584504 pessimistic information people 0.566128	CLICK HERE
1987	National Cancer Institute	Html	es	Tratamiento de los tumores embrionarios del sistema nervioso central infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del meduloblastoma infantil, los tumores embrionarios distintos del meduloblastoma y los tumores pineales infantiles.	sumario versa 0.501558 siguientes procedimientos 0.502311 células madre 0.524991 efectos secundarios meses 0.503043 siguientes aspectos 0.500523 años edad 0.500492 tratamiento mejora 0.501438 dosis pequeñas administras 0.501281 PDQ Descripción 0.501938 sección información 0.50094 efectos tardíos 0.505196 carcinoma nevoide 0.50085 PDQ Tumores 0.506016 PDQ Efectos tardíos 0.501814 líquido cefalorraquídeo 0.521206 punción espinal.Ampliar 0.500903 National Cancer Institute 0.5005 tumores benignos 0.508351 siguientes riesgos 0.500413 médula ósea.ampliar aspiración 0.502403 Instituto Nacional 0.501732	PDQ Tratamiento 0.505028 presente sumario 0.501062 determinados cambios 0.501002 riesgo promedio 0.513411 nuevos tipos 0.500625 riesgo alto.Riesgo promedio 0.501723 sistema nervioso central 0.814928 Physician Data Query 0.50178 brain tumor 0.501055 prueba irm 0.500762 Aboutâ„¢ Brain Tumors 0.500627 siguientes enfermedades 0.501038 cuánto tumor 0.503396 tumores embrionarios 0.994005 imágenes seguirán 0.500378 Cuánto tiempo 0.500383 siguientes enlaces 0.500476 SNC infantil recidivantes 0.502864 Brain Tumor Consortium 0.501941 infantil recidivantes 0.502523 siguientes pruebas 0.501153	CLICK HERE
2039	National Cancer Institute	Html	es	Exámenes de detección del cáncer de piel (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar sistemáticamente el cáncer de piel.	skin cancer 0.943888 pediatric melanoma 0.526248 cutaneous melanoma 0.524708 incidence estimate 0.432333 pediatric melanoma mortality 0.475024 Waldmann A 0.448643 pruebas directas 0.467472 accessed october 0.431704 American Cancer Society 0.752465 largo plazo 0.427741 incidencia promedio 0.427245 Am Acad Dermatol 0.559713 Skin biopsy 0.467836 CA Cancer 0.436346 Preventive Services Task 0.49324 Melanoma mortality following 0.47412 Instituto Nacional 0.477662 diagnosing melanoma 0.465782 Melanoma Pathology Study 0.472332 PDQ Exámenes 0.446099 malignant skin tumors 0.44617 Skin biopsy utilization 0.44782 Estados Unidos 0.486058 study comparing trends 0.42068 Skin biopsy rates 0.447638	JAMA Dermatol 0.430327 US Preventive Services 0.448303 melanoma incidence among 0.478575 Nolte S 0.427295 Rogers HW 0.427126 consecuencias adversas 0.434206 Gandini S 0.430629 estudio screen 0.45426 United States 0.464438 Arch Dermatol 0.504577 Cancer Facts 0.476716 Weinstock MA 0.509901 National Cancer Institute 0.43929 Systematic skin 0.44278 population-based screening intervention 0.428982 Services Task Force 0.491749 radiación uv 0.425917 Dermatol Surg 0.429711 systematic review 0.43149 melanoma mortality 0.579785 BMC Cancer 0.438009 malignant melanoma 0.574467 nonmelanoma skin cancer 0.673873 Lott JP 0.429356	CLICK HERE
3521	National Cancer Institute	Html	en	NCI-MATCH Trial (Molecular Analysis for Therapy Choice)	Information about the NCI-MATCH precision medicine trial, in which patients with advanced solid tumors and lymphomas are assigned to treatment arms based on the molecular profiles of their disease.	NCI-MATCH trial 0.544063 rare cancer 0.541344 COMET study 0.578429 genetic makeup 0.540259 trial 0.805751 clinical trial tracking 0.631222 usual genomic testing 0.608947 National Clinical Trials 0.604691 MATCH protocol summary 0.637152 treatment arms 0.751732 clinical trials 0.747821 newly enrolling patients 0.642185 MATCH trial 0.634351 health care professionals 0.58508 cancer care 0.539135 patients 0.983397 cancer patients 0.598511 tumor gene testing 0.590848 ECOG-ACRIN Cancer Research 0.612355 non-small cell lung 0.606702 objective response rate 0.771639 medicine cancer treatment 0.706859 genomic sequencing 0.623041 treatment arms address 0.659842	gene sequencing lab 0.599434 specific genetic change 0.644953 laboratory method 0.524995 Cancer Trials Support 0.616424 potential MATCH participants 0.636971 cancer cells 0.549314 common genetic changes 0.635293 Cancer Information Service 0.610926 clinical trial. 0.538943 genetic change 0.741928 adult trial groups 0.623508 health insurance company 0.59001 enrolled patients 0.575046 progression-free survival 0.609538 specific genetic changes 0.64881 NCI Community Oncology 0.61311 particular genetic change 0.630183 new tumor biopsy 0.621774 genetic changes 0.811113 MATCH treatment arm 0.848463 Caris Life Sciences 0.607515 NRG Oncology Group 0.586136 advanced solid tumors 0.669501 new clinical sites 0.600949	CLICK HERE
16833	National Cancer Institute	Html	en	News and Events	The latest news from the Office of Cancer Nanotechnology Research and the Alliance, as well as upcoming and past events attended by the Office of Cancer Nanotechnology Research staff, and relevant upcoming scientific meetings.	National Cancer Institute 0.924974		CLICK HERE